Navidea biopharmaceuticals announces acceptance of abstract for presentation at the tumor myeloid-directed therapies summit annual meeting

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced acceptance of its abstract titled, “cd206 targeted delivery of bisphosphonate payloads alter human macrophage phenotypes towards m1-like” for presentation of a poster at this year's tumor myeloid-directed therapies summit. the 2nd annual tumor myeloid-directed therapie
NAVB Ratings Summary
NAVB Quant Ranking